mavyret

AbbVie and their full-service agency, FCB Health, contracted Brandsymbol to assist with expedited creative name development for their “next-gen HCV (Hepatitis C Virus) combination.” Completing an in-depth evaluation from a trademark, linguistics, safety, and regulatory perspective on their created names on an accelerated timeline, our team played an integral role in the approval of MAVYRET™. Brandsymbol also developed the final submission reports for the FDA and Health Canada, resulting in the approval of MAVYRET ™ in August 2017.